Search
Vera Therapeutics Inc
VERAAdd to Watchlist
33.050USD
-3.210-8.85%
Close 09-23 16:00（ET）
2.37BMarket Cap
LossP/E TTM
About Vera Therapeutics Inc Company
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.
Vera Therapeutics Inc Profile
Ticker SymbolVERA
Company nameVera Therapeutics Inc
IPO dateMay 14, 2021
CEOFordyce (Marshall)
Number of employees112
Security typeOrdinary Share
Fiscal year-endMay 14
Address2000 Sierra Point Parkway, Suite 1200
CityBRISBANE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94005
Phone16507700077
Websitehttps://veratx.com/
Ticker SymbolVERA
IPO dateMay 14, 2021
CEOFordyce (Marshall)
Company Executives of Vera Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Marshall Fordyce, M.D.
Dr. Marshall Fordyce, M.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
288.54K
--
Dr. Marshall Fordyce, M.D.
Dr. Marshall Fordyce, M.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
288.54K
--
Dr. Marshall Fordyce, M.D.
Dr. Marshall Fordyce, M.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
288.54K
--
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
135.56K
--
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
135.56K
--
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
135.56K
--
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
Independent Director
Independent Director
17.49K
--
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
Independent Director
Independent Director
17.49K
--
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
Independent Director
Independent Director
17.49K
--
Ms. Christy Oliger
Ms. Christy Oliger
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Marshall Fordyce, M.D.
Dr. Marshall Fordyce, M.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
288.54K
--
Dr. Marshall Fordyce, M.D.
Dr. Marshall Fordyce, M.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
288.54K
--
Dr. Marshall Fordyce, M.D.
Dr. Marshall Fordyce, M.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
288.54K
--
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
135.56K
--
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
135.56K
--
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
135.56K
--
FAQs
Who are the top five shareholders of Vera Therapeutics Inc?
The top five shareholders of Vera Therapeutics Inc are: Dr. Marshall Fordyce, M.D.
How many institutions hold shares of Vera Therapeutics Inc (VERA)?
As of 2026Q1, 453 institutions hold shares of Vera Therapeutics Inc, with a combined market value of approximately 86.22M, accounting for 120.11% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 708577.00.